(lp0
S'Alnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It Motley Fool - Feb 9, 2017 The Medicines Company  presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with&nbsp;...Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ... - Business Wire Alnylam  Q3 Loss Narrower than Expected, Revenues Rise - Nasdaq'
p1
aS"Better Buy: bluebird bio, Inc. vs. Alnylam Pharmaceuticals Motley Fool - Feb 28, 2017 RNAi expert Alnylam Pharmaceuticals'  major decline came more recently in October, when the company ended a phase 3 trial testing its lead drug revusiran in patients with hereditary ATTR amyloidosis with cardiomyopathy. The clinical trial&nbsp;...How Do Analysts View Alnylam Pharmaceuticals in 2017? - Market Realist"
p2
aS'The Medicines Company and Alnylam Pharmaceuticals Report Positive Final ... Yahoo Finance - Mar 17, 2017 The Medicines Company  and Alnylam Pharmaceuticals, Inc.  today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment ...Alnylam touts latest trial data as suggesting its drugs are safe - Boston Business Journal'
p3
aS'Option Market Alert: Alnylam Pharmaceuticals Inc Implied Price Swing Hits An ... CML News - 16 hours ago No Risk Alert Here: Before we dive into any analysis we simply note that Alnylam Pharmaceuticals Inc  risk is neither elevated nor depressed.'
p4
aS'Alnylam Pharmaceuticals, Inc.  Rating Lowered to Hold at Credit Suisse ... Petro Global News 24 - Mar 21, 2017 Alnylam Pharmaceuticals, Inc.  was downgraded by research analysts at Credit Suisse Group AG to a hold rating in a research report issued to clients and investors on Monday.Alnylam Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 21 - Equities.comAnalyst Activity  FBR &amp; Co Reiterates Buy on Alnylam Pharmaceuticals (NASDAQ ... - Market Exclusive'
p5
aS'Alnylam Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 17 Equities.com - Mar 17, 2017 Alnylam Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock gained 1.41% to close at $55.25.Alnylam Pharmaceuticals, Inc.  Upgraded by Vetr Inc. to Strong-Buy - Chaffey BreezeIs It Time to go for Alnylam Pharmaceuticals, Inc. , Envision Healthcare ... - StockNewsJournal'
p6
aS"Drilling Down Into the Charts for Alnylam Pharmaceuticals, Inc.  The USA Commerce - Mar 20, 2017 We have gathered the technical data on Alnylam Pharmaceuticals, Inc. , and see some interesting trends in the stock's behavior of late."
p7
aS'Why Analysts put forward these two stocks: Alnylam Pharmaceuticals, Inc. (ALNY ... The USA Commerce - Mar 21, 2017 Presently Alnylam Pharmaceuticals, Inc.  stock have an ABR of 2.10. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.'
p8
aS'What is the Street Saying About Alnylam Pharmaceuticals, Inc. ? Aiken Advocate - Mar 20, 2017 Analysts and investors are typically highly focused on company earnings numbers when they are published. Company earnings are a good way to analyze the profitability of the company. Sell-side analysts are currently looking for Alnylam Pharmaceuticals,&nbsp;...'
p9
aS'Alnylam Pharmaceuticals, Inc.  Stock Support And Resistance Levels USA Commerce Daily - 19 hours ago With all other things going on, Alnylam Pharmaceuticals, Inc.  has been on a run - rising 38.44 percent in just three months.'
p10
a.